Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function

American Journal of Physiology

Volumn 272, Issue 4 PART 2, 1997, Pages

  Kömhoff, Martin ^a   Gröne, Hermann Josef ^a   Klein, Thomas ^a   Seyberth, Hannsjoerg W ^a   Nüsing, Rolf M ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Nephrogenesis; Nonsteroidal anti inflammatory drug; Podocyte; Prostaglandins

Indexed keywords

EID: 33745382414     PISSN: 00029513     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bach-, K. F., and R. Jacobson. Arachidonic acid metabolism and the kidney. In: The Kidney (4th ed.), edited by B. M. Brenner and F. C. Rector. Philadelphia, PA: Saunders, 1990, p. 584-622.
2. Berl, T., W. L. Heinrich, A. L. Erickson, and R. W. Schrier. Prostaglandins in the beta-adrenergic and baroreceptor-mediated secretion of renin. Am. J. Physiol. 236 (Renal Fluid Electrolyte Physiol. 5): F472-F477, 1979.
3. Blackshear, J. L., W. S. Spielman, F. G. Knox, and J. C. Romero. Dissociation of renin release and renal vasodilation by prostaglandin synthesis inhibitors. Am. J. Physiol. 237 (Renal Fluid Electrolyte Physiol. 6): F20-F24, 1979.
4. Breyer, M. D., and Y. Ando. Hormonal signaling and regulation of salt and water transport in the collecting duct. Annu. Reu. Physiol. 56: 711-739, 1994.
5. Cupples, W. A., T. Sakai, and D. J. Marsh. Angiotensin II and prostaglandins in control of vasa recta blood flow. Am. J. Physiol. 254 (Renal Fluid Electrolyte Physiol. 23): F779-F784, 1985.
6. Data, J. L., J. C. Gerber, W. J. Crump, J. C. Frolich, J. W. Hollifield, and A. S. Nies. The prostaglandin system. A role in the canine baroreceptor control of renin release. Circ. Res. 42: 454-458, 1978.
7. Dinchuk, J. E., B. D. Car, R. J. Focht, J. J. Johnston, B. D. Jaffee, M. B. Covington, N. R. Contel, V. M. Eng, R. J. Collins, P. M. Czerniak, S. Gorry, and J. Trzakos. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378: 406-409, 1995.
8. Drenckhahn, D., and R. P. Franke. Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man. Lab. Invest. 59: 673-682, 1988.
9. Emery, P. Pharmacology, safety data and therapeutics of COX-2 inhibitors. In: Improved Non-Steroidal Anti-Inflammatory Drugs, edited by J. Vane, J. Bolting, and R. Botting. Dordrecht, Netherlands. Kluwer, 1996, p. 229-242.
10. 2 and angiogenesis. Proc. Soc. Exp. Biol. Med. 172: 214-218, 1983.
11. Harada, S., J. A. Nagy, K. A. Sullivan, K. A. Thomas, N. Endo, G. A. Rodan, and S. B. Rodan. Induction of vascular endothelial growth factor expression by prostaglandin E2 and El in osteoblasts. J. Clin. Invest. 93: 2490-2496, 1994.
12. Harris, R. C., J. A. McKanna, Y. Akai, H. R. Jacobson, R. N. Dubois, and M. D. Breyer. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest. 94: 2504-2510, 1994.
13. Hebert, R. L., R. M. Breyer, H. R. Jacobson, and M. D. Breyer. Functional and molecular aspects of prostaglandin E receptors in the cortical collecting duct. Can. J. Physiol. Pharmacol. 73: 172-179, 1995.
14. Kaplan, B. S., I. Restaino, D. S. Raval, R. P. Gottlieb, and J. Bernstein. Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr. Nephrol. 8: 700-4, 1994.
15. Kriz, W., E. Hackenthal, R. Nobiling, T. Sakai, M. Elger, and B. Hahnel. A role for podocytes to counteract capillary wall distension. Kidney Int. 45: 369-376, 1994.
16. Kujubu, D. A., B. S. Fletcher, B. C. Varnum, R. W. Lim, and H. R. Herschman. TIS10, a phorbol ester tumor promoter-inducible mRNAfrom Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266: 12866-12872,1991.
17. Langenbach, R., S. G. Morham, H. F. Tiano, C. D. Loftin, B. I. Ghanayem, P. C. Chulada, J. F. Mahler, C. A. Lee, E. H. Goulding, K. D. Kluckman, H. Kim and O. Smithies. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulcération. Cell 83: 483-492, 1995.
18. Laurens, W., C. Battaglia, C. Foglieni, R. De Vos, B. Malanchini, B. Van Damme, Y. Vanrenterghem, G. Remuzzi, and A. Remuzzi. Direct podocyte damage in the single nephron leads to albuminuria in vivo. Kidney Int. 47: 1078-1086, 1995.
19. Masferrer, J. L., B. S. Zweifel, P. T. Manning, S. D. Hauser, K. M. Leahy, W. G. Smith, P. C. Isakson, and K. Seibert. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA 91: 3228-3232, 1994.
20. Morham, S. G., R. Langenbach, C. D. Loftin, H. F. Tiano, N. Vouloumanos, J. C. Jennette, J. F. Mahler, K. D. Kluckman, A. Ledford, C. A. Lee, and O. Smithies. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83: 473-482, 1995.
21. Nüsing, R., G. Sauter, P. Fehr, U. Durmuller, M. Kasper, F. Gudat, and V. Ullrich. Localization of thromboxane synthase in human tissues by monoclonal antibody Tu 300. Virchows Arch. A Pathol. Anat. Histopathol. 421: 249-254, 1992.
22. Nüsing, R., M. P. Wernet, and V. Ullrich. Production and characterization of polyclonal and monoclonal antibodies against human thromboxane synthase. Blood 76: 80-5, 1990.
23. O'Neill, G. P., and A. W. Ford-Hutchinson. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEES Lett. 330: 156-160, 1993.
24. Otto, J. C., and W. L. Smith. Prostaglandin endoperoxide synthases-1 and -2. J. Lipid Mediators Cell Signalling 12: 139-156,1995.
25. Palmer, B. F. Renal complications associated with use of nonsteroidal anti-inflammatory agents. J. Invest. Med. 43: 516-533, 1995.
26. Rosen, G. D., T. M. Birkenmeier, A. Raz, and M. J. Holtzman. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. Biochem. Biophys. Res. Commun. 164: 1358-1365, 1989.
27. Seyberth, H. W., W. Rascher, R. Hackenthal, and L. Wille. Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very-low-birth-weight infants with symptomatic patent ductus arteriosus. J. Pediatr. 103: 979-984, 1983.
28. Siegle, I., R. Nüsing, R. Brugger, R. Sprenger, R. Zecher, and V. Ullrich. Characterization of monoclonal antibodies generated against bovine and porcine prostacyclin synthase and quantitation of bovine prostacyclin synthase. FEES Lett. 347: 221-225, 1994.
29. Simon, M., H. J. Gröne, O. Johren, J. Kullmer, K. H. Plate, W. Risau, and E. Fuchs. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am. J. Physiol. 268 (Renal Fluid Electrolyte Physiol. 37): F240-F250,1995.
30. Smith, W. L., and T. G. Bell. Immunohistochemical localization of the prostaglandin-forming cyclooxygenase in renal cortex. Am. J. Physiol. 235 (Renal Fluid Electrolyte Physiol. 4): F451-F457,1978.
31. Van Der Heijden, B. J., C. Carlus, F. Narcy, F. Bavoux, A. L. Delezoide, and M. C. Gubler. Persistent anuria, neonatal death, and renal microcystic lesions after prenatal exposure to indomethacin. Am. J. Obstet. Gynecol. 171: 617-623, 1994.
32. Walker, R. M., R. S. Brown, and J. S. Stoff. Role of renal prostaglandins during antidiuresis and water diuresis in man. Kidney Int. 21: 365-370, 1981.
33. Zeidel, M. Z. Hormonal regulation of inner medullary collecting duct sodium transport. Am. J. Physiol. 265 (Renal Fluid Electrolyte Physiol. 34): F159-F173, 1993.